United States' factor XI-deficiency patients need a safer treatment

American Journal of Hematology

Volumn 80, Issue 4, 2005, Pages 301-302

  Aledort, Louis M ^a   Goudemand, Jenny ^b   Callum, Jeannie ^c   Guerin, Viviane ^c   Kenet, G ^c   Poon, Man Chiu ^c   Spertini, Olivier ^c   Thomas, Mari ^c  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Centre Hospitalier Universitaire   (France)

^c Box 1006 ^*

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 11; FRESH FROZEN PLASMA; HEMOLEVEN; HEPARIN;

ANAPHYLAXIS; BLOOD CLOTTING FACTOR 11 DEFICIENCY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MANUFACTURE; DRUG MARKETING; DRUG SAFETY; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; PREVALENCE; PRIORITY JOURNAL; REVIEW; SUBSTITUTION THERAPY; THROMBOSIS; UNITED STATES; VIRUS INACTIVATION;

EID: 28544441971     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.20565     Document Type: Review

References (10)

1. Bolton-Maggs PHB, Perry DJ, Chalmers EA, et al. The rare coagulation disorders review with guidelines for management from the United Kingdom Haemophilia Centre Doctors' Organisation. Haemophilia 2004;10(5):593-628.
2. Aledort LM, Forster A, Maksoud J, Isola L. BPL factor XI concentrate: clinical experience in the USA. Haemophilia 1997;3: 59-62.
3. Burnouf-Radosevich M, Burnouf T. A therapeutic, highly purified factor XI concentrate from human plasma. Transfusion 1992;32(9): 861-867.
4. Burnouf-Radosevich M, Appourchaux P, Huart JJ, Burnouf T. Nanofiltration, a new specific virus elimination method applied to high-purity factor IX and factor XI concentrates. Vox Sang 1994; 67(2):132-138.
5. Alvarez MT, Canales M, Villar A, et al. Factor XI deficiency associated with von Willebrand disease. Blood Abstr 1998;10: abstract 2285.
6. nd ESCP-ACCP Joint Meeting, Clinical Pharmacy Congress, 28-30 April 2004, Paris, France.
7. Cobo Rodriguez T, Jimenez Yuste V, Chaves-Machado R, Villar-Camacho A, Quintana-Molina M, Hernandez Navarro F. Factor XI (FXI) deficiency, single-centre experience in management of patients undergone to surgery under treatment with FXI concentrate (Hemoleven). Haemophilia 2004;10(Suppl 3):7.
8. Goudeniand J, Aurousseau MH, David B, et al. A four-year experience of a pure factor XI concentrate. Haemophilia 1996; 2(Suppl 1):13.
9. Mannucci PM, Bauer KA, Santagostino E, et al. Activation of the coagulation cascade after infusion of a factor XI concentrate in congenitully deficient patients. Blood 1994;84:1314-1319.
10. De Raucourt E, Aurousseau MH, Denninger MH, Verroust F, Goudeniand M, Fischer AM. Use of a factor XI concentrate in three severe factor XI-deficient patients. Blood Coagul Fibrinolysis 1995;6:486-487.